-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Next generation sequencing
-
Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice
By Kara Nyberg, PhD Posted: June 24, 2020 Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically improve patient outcomes. Up to 85% of patients with lung cancer harbor potentially actionable driver mutations, and matching targeted therapy to druggable alterations in the first-line setting prolongs survival…
-
Time to End the Debate on Genomic Testing in NSCLC
By Nathan Pennell, MD, PhD Posted: April 16, 2020 It’s an exciting time to be a thoracic oncologist. We live in an era of unprecedented discovery in medicine—and in oncology in particular—with basic scientific breakthroughs such as targetable driver oncogenes translating into highly effective treatments for patients in record time. In my relatively short career,…
-
TRK Inhibition in TRK Fusion–Positive Lung Cancers
By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. These fusions are found at high frequencies (> 90% in select series) in rare cancers such as secretory carcinoma and at lower frequencies in more…
-
Experts Discuss Turnaround Times, Geographic Differences Regarding Liquid Biopsy
Improved Turnaround Times for Biopsy Results Matters More Than Type of Biopsy By Dr. Edgardo S. Santos Castillero, MD, FACP Posted: December 11, 2019 Dr. Edgardo S. Santos Castillero Regarding “Liquid Biopsy for Assessing Response or Progression in Advanced NSCLC” by Dr. Geoffrey R. Oxnard published in the October issue of the IASLC Lung Cancer News, I…
View ILCN Archives
Provider Resources
Popular Articles